|
|
Volumn 320, Issue 8, 2018, Pages 751-752
|
|
Comparison of 2 treatment models precision medicine and preventive medicine
a,b
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIHYPERTENSIVE AGENT;
BLOOD CLOTTING FACTOR 9;
GEFITINIB;
IMATINIB;
RECOMBINANT BLOOD CLOTTING FACTOR 9;
VEMURAFENIB;
WARFARIN;
ANTIHYPERTENSIVE THERAPY;
CANCER PATIENT;
CANCER SURVIVAL;
CARDIOLOGY;
CARDIOVASCULAR RISK;
CEREBROVASCULAR ACCIDENT;
CLINICAL OUTCOME;
COST EFFECTIVENESS ANALYSIS;
ENVIRONMENT;
FOLLOW UP;
FOOD AND DRUG ADMINISTRATION;
GENE;
GENE MUTATION;
GENE THERAPY;
GENETIC ASSOCIATION;
GENETIC RISK;
GENETIC VARIABILITY;
HEART INFARCTION;
HEMOPHILIA B;
HIGH RISK POPULATION;
HUMAN;
HYPERLIPIDEMIA;
HYPERTENSION;
INTERMETHOD COMPARISON;
LEUKEMIA;
LIFESTYLE;
MELANOMA;
NON SMALL CELL LUNG CANCER;
NOTE;
ONCOLOGY;
PERSONALIZED MEDICINE;
PREDICTION;
PRESCRIPTION;
PREVENTIVE MEDICINE;
PRIORITY JOURNAL;
PROGRESSION FREE SURVIVAL;
RISK BENEFIT ANALYSIS;
RISK FACTOR;
RISK REDUCTION;
SMOKING CESSATION;
TREATMENT RESPONSE;
UNIVERSITY HOSPITAL;
COMPARATIVE STUDY;
HUMANS;
PRECISION MEDICINE;
PREVENTIVE MEDICINE;
|
|
EID: 85052591990
PISSN: 00987484
EISSN: 15383598
Source Type: Journal
DOI: 10.1001/jama.2018.8377 Document Type: Note |
|
Times cited : (48)
|
|
References (7)
|
